Werewolf Therapeutics (NASDAQ:HOWL) Announces Quarterly Earnings Results

by · The Markets Daily

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36, FiscalAI reports. The firm had revenue of $21.00 million for the quarter.

Werewolf Therapeutics Trading Down 29.4%

Shares of HOWL stock traded down $0.15 on Friday, hitting $0.35. 2,949,032 shares of the stock were exchanged, compared to its average volume of 577,268. The firm has a market capitalization of $17.16 million, a P/E ratio of -0.28 and a beta of 0.30. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.38. The business has a 50-day moving average of $0.39 and a 200 day moving average of $0.60.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of research analyst reports. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Read Our Latest Research Report on HOWL

Insider Buying and Selling

In other Werewolf Therapeutics news, Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total transaction of $145,918.85. Following the transaction, the insider directly owned 303,719 shares of the company’s stock, valued at $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,634,670 shares of company stock worth $1,751,888. 23.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of HOWL. Regal Investment Advisors LLC increased its position in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its stake in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Featured Stories